Skip to main content

What the FDA labels say about taking them together

Carvedilol and cobicistat

Cobicistat's FDA label of February 10, 2026 names carvedilol in its drug interactions section; the carvedilol labels PlainMeds reads (2) do not name cobicistat. The cobicistat label: “Clinical monitoring is recommended for coadministration with beta-blockers that are metabolized by CYP2D6.”

Check it at the source: the carvedilol FDA label on DailyMed (effective July 31, 2026, Waylis Therapeutics LLC); the cobicistat FDA label on DailyMed (effective February 10, 2026, Gilead Sciences, Inc.).

What does the carvedilol label say about cobicistat?

Carvedilol's label (effective July 31, 2026) and its 1 other brand-application label do not name cobicistat in these sections. A label lists what its studies and reports found; it is not a complete list.

Source: FDA drug label (Coreg), Waylis Therapeutics LLC, effective July 31, 2026 (SPL set 07c619c6-4a0c-445e-94fa-664a54f68a39), via openFDA; the full label on DailyMed

What does the cobicistat label say about carvedilol?

Cobicistat label, drug interactions

Concomitant Drug Class/Drug Name: Beta-Blockers: e.g., metoprolol carvedilol timolol; Potential Effect ↑ = Increase, ↓ = Decrease, ↔ = No change: ↑ beta-blockers; Clinical Comment: Clinical monitoring is recommended for coadministration with beta-blockers that are metabolized by CYP2D6.

Source: FDA drug label (Tybost), Gilead Sciences, Inc., effective February 10, 2026 (SPL set 3784c35c-e87f-410c-900b-8fd6313c6010), via openFDA; the full label on DailyMed

These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.

Both medicines on the record

41Carvedilol generic labelers
0Cobicistat generic labelers
CarvedilolCobicistat
Labeled forHeart failure, High blood pressureHIV
Boxed warningNoNo
Pharmacy cost (NADAC)$0.0179 per tablet 6.25 mg tabletn/a
Shortage nowNo current entryA presentation being discontinued

Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)

What next?